|
|
Volumn 8, Issue 12, 2009, Pages 922-
|
|
Deal watch: Alcon licenses complement pathway inhibitor for macular degeneration.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYCLOPEPTIDE;
POT 4 PEPTIDE;
POT-4 PEPTIDE;
AGED;
COMPLEMENT ACTIVATION;
DRUG DELIVERY SYSTEM;
DRUG DESIGN;
DRUG EFFECT;
DRUG INDUSTRY;
HUMAN;
NEOVASCULARIZATION (PATHOLOGY);
NOTE;
PATHOPHYSIOLOGY;
RETINA MACULA DEGENERATION;
AGED;
COMPLEMENT ACTIVATION;
DRUG DELIVERY SYSTEMS;
DRUG DESIGN;
DRUG INDUSTRY;
HUMANS;
MACULAR DEGENERATION;
NEOVASCULARIZATION, PATHOLOGIC;
PEPTIDES, CYCLIC;
|
|
EID: 73449106495
PISSN: None
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3063 Document Type: Note |
|
Times cited : (8)
|
|
References (0)
|